Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors

Aghajanian, 1997, Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells, Neuropharmacology, 36, 589, 10.1016/S0028-3908(97)00051-8 Baraban, 1980, Suppression of serotonergic neuronal firing by alpha-adrenoceptor antagonists: evidence against GABA mediation, Eur. J. Pharmacol., 66, 287, 10.1016/0014-2999(80)90461-6 Cartmell, 2000, Attenuation of specific PCP-evoked behaviors by the potent mGluR2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine, Psychopharmacology, 148, 423, 10.1007/s002130050072 Cartmell, 2000, Regulation of neurotransmitter release by metabotropic glutamate receptors, J. Neurochem., 75, 889, 10.1046/j.1471-4159.2000.0750889.x Chaki, 2004, MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity, Neuropharmacology, 46, 457, 10.1016/j.neuropharm.2003.10.009 Conn, 1997, Pharmacology and functions of metabotropic glutamate receptors, Annu. Rev. Pharmacol. Toxicol., 37, 205, 10.1146/annurev.pharmtox.37.1.205 Danysz, 1995, Glutamate in CNS disorders, Drug News Perspect., 8, 261 Detke, 1995, Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants, Psychopharmacology, 121, 66, 10.1007/BF02245592 Graham, 1971, Effects of amphetamine on single cell activity in a catecholamine nucleus, the locus coeruleus, Nature, 234, 100, 10.1038/234100b0 Grillon, 2003, Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans, Psychopharmacology, 168, 446, 10.1007/s00213-003-1444-8 Helton, 1998, Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors, J. Pharmacol. Exp. Ther., 284, 651 Jodo, 1998, Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons, Neuroscience, 83, 63, 10.1016/S0306-4522(97)00372-2 Malberg, 2000, Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus, J. Neurosci., 20, 9104, 10.1523/JNEUROSCI.20-24-09104.2000 Marek, 2000, Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex, J. Pharmacol. Exp. Ther., 292, 76 Martin-Ruiz, 2001, Control of serotonergic function in medial prefrontal cortex by serotonin-2A receptors through a glutamate-dependent mechanism, J. Neurosci., 21, 9856, 10.1523/JNEUROSCI.21-24-09856.2001 Meldrum, 2000, Glutamate as a neurotransmitter in the brain: review of physiology and pathology, J. Nutr., 130, 1007S, 10.1093/jn/130.4.1007S Nakazato, 2000, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists, J. Med. Chem., 43, 4893, 10.1021/jm000346k Paxinos, 1998 Shimazaki, 2004, Anxiolytic-like activity of MGS0039, a potent group II motabotropic glutamate receptor antagonist, in marble-burying behavior test, Eur. J. Pharmacol., 501, 121, 10.1016/j.ejphar.2004.08.016 Yoshimizu, 2004, Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039, Biochem. Biophys. Res. Commun., 315, 493, 10.1016/j.bbrc.2004.01.073